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Abstract
Background: Issues have been raised concerning the
robustness and validity of alleged serum markers dis-
covered by surface-enhanced laser desorption/ioni-
sation time-of-flight mass spectrometry (SELDI-TOF
MS). Pre-analytical variables have been shown to
exert a profound effect on protein profiles, irrespec-
tive of true biological variation. However, little is
known about the possible effects of sample storage
duration on protein profiles. We, therefore, aimed to
investigate the effects of extended storage duration
on the serum protein profile.
Methods: Archival sera from 140 breast cancer
patients, stored at –308C for 1–11 years, were profiled
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by SELDI-TOF MS using immobilised metal affinity
capture (IMAC) arrays, a condition applied in the
majority of breast cancer biomarker discovery
studies.
Results: Fourteen peak clusters, structurally identified
as C3a des-arginine anaphylatoxin and multiple frag-
ments of albumin and fibrinogen, were found to be
significantly associated with sample storage duration
by five distinct patterns. These proteins have been
described previously as potential cancer markers, ren-
dering them specific to both disease and sample
handling issues.
Conclusions: To prevent experimental variation being
interpreted erroneously as disease associated varia-
tion, assessment of potential confounding pre-ana-
lytical parameters is a pre-requisite in biomarker
discovery and validation studies. In addition, with
respect to the different (non-)linear patterns observed
in the current study, simply performing linear correc-
tions to account for sample storage duration will not
necessarily suffice.
Clin Chem Lab Med 2009;47:694–705.
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Introduction
In the last two decades, much effort has been devoted
to the search for improved markers that can be
applied in screening, diagnosis and prognosis of can-
cer. Genetic markers for cancer were initially pursued
by the investigation of the cancer genome. However,
it is currently understood that gene analysis by itself
provides an incomplete picture. Alternative splicing of
both mRNA and proteins, combined with more than
100 unique post-translational modifications, can
result in one gene giving rise to multiple protein spe-
cies (1). Thus, compared to the genome, the proteome
can provide a more dynamic and accurate reflection
of both the intrinsic genetic programme of the cell
and the impact of its immediate environment (2).
Since proteome analysis can provide the link between
gene sequence and cellular physiology (3), proteo-
mics is expected to complement gene analyses for
the detection of novel cancer markers (4).
Several different methods based on mass spec-
trometry (MS) have been applied to interrogate the
proteome. One of the technologies used extensively
for protein profiling is surface-enhanced laser desorp-
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tion/ionisation time-of-flight mass spectrometry (SEL-
DI-TOF MS) (5). This technology combines retentive
chromatography with laser desorption/ionisation MS
instrumentation, enabling high-throughput mass pro-
filing of highly complex biological samples such as
serum. Spectral patterns are compared across sample
groups to find discerning masses or differential
changes in peak intensities.
The majority of SELDI studies reported thus far
have evaluated serum, although the technology is
equally effective in analysing e.g., tissue lysates (6).
Serum is an easy to sample protein-rich body fluid
perfusing all tissues of the body and thus, theoreti-
cally, provides a good reflection of the human pro-
teome (7). In addition, existing serum banks could
readily provide serum from a large number of
patients allowing studies to be completed in a more
timely manner (8). Many reports have described the
successful application of SELDI-TOF MS in the dis-
covery of potential serum markers for different types
of cancer, such as ovarian (9), colorectal (10), and thy-
roid carcinoma (11). Issues, however, have been
raised concerning the robustness and validity of
alleged serum markers discovered by SELDI-TOF MS.
A potential drawback of analysing high-dimensional
proteomic (SELDI-TOF MS) data for disease-associat-
ed biomarkers is the propensity to discover patterns
resulting from pre-analytical artifacts in a given sam-
ple set, rather than from the pathology of interest (12).
Several lines of evidence indicate that pre-analytical
variables, such as sample collection, processing and
storage temperature can exert a profound effect on
protein profiles, regardless of the true biological var-
iation (13–15). Little is known about the possible
effects of the pre-analytical variable of sample storage
duration on the serum proteome. Although this
parameter has been investigated in two studies, only
very few sera (nF12), stored for relatively short
periods of time (1–3 months) were profiled (16, 17).
Clinical studies generally exceed these storage dura-
tions, since study sera either originate from sample
banks (18–20), or were collected prospectively over a
period of years (21). We have previously investigated
the effects of long-term storage (0–16 months) using
a larger sample size (ns150) (22). However, even this
extended storage interval is usually exceeded by clin-
ical proteomics studies. For example, McLerran et al.
(23) reported a storage interval of more than 20 years.
Following analysis of prospectively collected sera,
their initial results obtained using archival sera could
not be confirmed. After they subjected their initial
study to extensive post-study data analysis, they dis-
covered their study to be biased by sample storage
duration, as one confounding variable. Their study of
prostate cancer provides a clear example of the
potentially detrimental effects of this long-term stor-
age duration on clinical proteomics studies.
Although the study of McLerran is not unique in
analysing sera originating from a serum bank, the
influence of storage duration on serum protein pro-
files is seldomly investigated. We, therefore, investi-
gated the effects of extended storage duration of
1–11 years on the serum protein profile. We evaluated
archival sera from 140 breast cancer patients using
SELDI-TOF MS with immobilised metal affinity cap-
ture (IMAC30) arrays. We employed these settings
as they are commonly used in serum biomarker
discovery studies performed in breast cancer (18, 19,
21, 24–28). Peak clusters that were found to be sig-




Archival sera from 140 breast cancer patients, collected
between January 1993 and December 2002, were analysed
in our laboratory using standard analytical procedures. All
samples originated from the Netherlands Cancer Institute
serum bank. Samples were collected prior to therapy after
obtaining informed consent and approval by the Institutional
Review Board. Samples were collected into Venoject serum
tubes (Terumo Europe, Leuven, Belgium). After collection,
blood was allowed to coagulate for 30 min, and then centri-
fuged at room temperature for 10 min at 1700 g. Serum was
transferred into 1.8-mL polypropylene screw cap tubes
(Nunc CryoTubes, Thermofisher Scientific, Rochester, NY,
USA) and stored frozen at –308C from 9 to 128 months until
analysis.
Chemicals
All chemicals were obtained from Sigma (St. Louis, MO,
USA), unless stated otherwise.
Serum protein profiling
Serum protein profiling was performed using the Protein-
Chip SELDI Reader (Bio-Rad Labs, Hercules, CA, USA) with
IMAC30 arrays. Sera were analysed in three batches of 39,
47, and 54 samples on three consecutive days. Throughout
the assay, arrays were assembled in a 96-well bioprocessor
which was shaken on a platform shaker at 350 rpm. Arrays
were charged twice with 50 mL 100 mM nickel sulphate
(Merck, Darmstadt, Germany) for 15 min, followed by three
rinses with deionised water (Braun, Emmenbru¨cke, Germa-
ny) and two equilibrations with 200 mL phosphate buffered
saline (PBS; 0.01 M) pH 7.4/0.5 M sodium chloride/0.1%
TritonX-100 (binding buffer; sodium chloride from Merck) for
5 min. Sera were thawed on ice and denatured using a 1:10
dilution in 9 M urea/2% 3-w(3-cholamidopropyl)dimethyl-
ammonio-x-1-propanesulfonic acid (CHAPS). Pre-treated
samples were diluted 1:10 in binding buffer and randomly
applied in singlicate to the arrays. After a 30-min incubation
the arrays were washed 2 times with binding buffer and
twice with PBS pH 7.4/0.5 M sodium chloride for 5 min. Fol-
lowing a quick rinse with deionised water, arrays were air-
dried. A saturated solution of sinapinic acid (Bio-Rad Labs)
in 50% acetonitrile (ACN; Biosolve, Valkenswaard, The Neth-
erlands)/0.5% trifluoroacetic acid (TFA; Merck) was applied
twice (0.6 mL) to the arrays as the matrix. Following air-dry-
ing, the arrays were analysed using the ProteinChip SELDI
(PBSIIc) Reader. Data were collected between 0 and 100 kDa,
averaging 65 laser shots with intensity 200, detector sensi-
tivity 9, and a focus lag time of 636 ns (m/z 7000). For mass
accuracy, the instrument was calibrated on the day of meas-
urements with all-in-one peptide standard (Bio-Rad Labs).
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Statistics and bioinformatics
Spectra of the three batches were processed separately by
the ProteinChip Software v3.1 (Bio-Rad Labs). Spectra were
baseline subtracted, and then normalised to the total ion cur-
rent. Spectra with normalisation factors )2 or -0.5 were
excluded from further analysis.
Following pre-processing of the spectra, the Biomarker
Wizard (BMW) software package was used for peak detec-
tion. Peaks were auto-detected when they occurred in at
least 30% of spectra and had a signal-to-noise ratio (S/N) of
at least 7. Peak clusters were completed by peaks with a
S/N of at least 5 in a cluster mass window of 0.4%. Peak
information was exported as spreadsheet files. The batches
were analysed on three consecutive days, a parameter which
can influence spectral data (29, 30). Merging peak intensity
data from the three sets would likely lead to spurious results.
Thus, the intensities of peaks occurring across all three sam-
ple sets were log transformed per sample set to obtain nor-
mal distributions. The log transformed peak intensities were
then converted to standard Z-value scores for each sample
set. This was accomplished by subtracting the mean and
dividing by the SD. The log-Z transformed data of the three
sets were merged in one file.
To investigate the effect of sample storage time on peak
expression, samples were split into four categories of differ-
ing duration of sample storage (F32 months, ns16;
32–64 months, ns59; 64–96 months, ns48; )96 months,
ns17). Mean peak intensity differences between each of the
four categories were evaluated using ANOVA. We corrected
p-values for multiple testing using Bonferroni correction.We
performed this correction by multiplying the p-values with
the number of peak clusters detected (ns76). We also inves-
tigated the relationship between peak intensity and sample
storage time as a function of patients’ age and/or stage of
disease. We accomplished this by dividing the samples into
age-specific tertiles (F49.4, 49.5–61.8, and )61.8 years), or
according to the stage of disease (Stage 2A or 2B). Mean
peak intensity differences between age-specific tertiles were
investigated using ANOVA and the t-test was used to eval-
uate differences with respect to stage of disease. Time-asso-
ciated clusters that were significantly related to patients’ age
and/or stage of disease were further investigated. The rela-
tionship between peak intensity and storage duration was
investigated in subgroups of age (i.e., - or ) median age)
and stage (i.e., Stage 2A or 2B). Statistical analyses were
performed using SPSS statistical software, version 13.0
(SPSS Inc., Chicago, IL, USA).
Protein purification and identification
Five hundred microliter of serum, containing the proteins
significantly associated with sample storage duration, was
denatured in 9 M urea/2% CHAPS/50 mM Tris-HCl pH 9. The
sample was then fractionated on Q Ceramic HyperD beads
with a strong anion exchange moiety (Biosepra Inc., Mal-
borough, MA, USA). The flow-through was collected, and
bound proteins were eluted using buffers with pH from 9 to
3. The fractions containing proteins of interest were further
purified by size fractionation using Microcon 50 kDa MW
spin concentrators (YM50, Millipore, Billerica, MA, USA) with
increasing concentrations of ACN/TFA 0.1%. The filtrates
containing the proteins of interest were de-salted by appli-
cation on reversed phase RP18 beads (Varian Inc., Palo Alto,
CA, USA), followed by elution with increasing concentra-
tions of ACN/TFA 0.1%. The purification process was moni-
tored by profiling each fraction on IMAC30 Ni arrays and
NP20 arrays; a non-selective, silica chromatographic surface.
Eluates containing the proteins of interest were dried and re-
dissolved in loading buffer for sodium dodecylsulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Gel elec-
trophoresis was performed on Novex NuPage gels (18% Tris-
Glycine gel; Invitrogen, San Diego, CA, USA). Following
staining with colloidal Coomassie stain (Simply Blue; Invitro-
gen), protein bands of interest were excised and collected.
The proteins within the excised bands were eluted by wash-
ing twice with 30% ACN/100 mM ammonium bicarbonate,
followed by dehydration in 100% ACN. Next, gel bands were
heated at 508C for 5 min and eluted with 45% formic acid/
30% ACN/10% isopropanol under sonification for 30 min.
The eluates were left overnight at room temperature and
dried the following day. They were then re-suspended in
20 ng/mL trypsin (Promega, Madison, WI, USA) in 10% ACN/
25 mM ammonium bicarbonate, followed by incubation at
room temperature for 4 h. The tryptic digests were profiled
on NP20 chips, using 1 mL 20% a-cyano-4-hydroxy cinna-
minic acid (Bio-Rad Labs) in 50% ACN/0.5% TFA as matrix.
Peptides in the digests were investigated with the NCBI data-
base using the ProFound search engine at http://
prowl.rockefeller.edu/prowl-cgi/profound.exe. We used the
following search parameters: standard cleavage rules for
trypsin, one missed cleavage allowed. Confirmation of pro-
tein identity was provided by sequencing tryptic digest pep-
tides by quadrupole-TOF (Q-TOF) MS (Applied Biosystems/
MSD Sciex, Foster City, CA, USA) fitted with a ProteinChip
Interface (PCI-1000). Fragment ion spectra resulting from Q-
TOF analyses were used to search the SwissProt 44.2 data-
base (Homo Sapiens: 11,072 sequences) with the MASCOT
search engine at www.matrixscience.com (Matrix Science
Ltd., London, UK). We used the following search parameters:
monoisotopic precursor mass tolerance: 40 ppm, fragment
mass tolerance: 0.2 Da, variable modifications: methionine
oxidation, and trypsin cleavage site. Further confirmation of
protein identity was performed by immunoassay on
Protein A beads using the appropriate antibodies. Beads
were loaded with antibody in PBS, washed twice with PBS,
incubated for 30 min with whole serum, and then washed 5
times with PBS and once with deionised water. Bound pro-
teins were subsequently eluted using 0.1 M acetic acid, and
eluates were profiled on NP20 arrays. The extent of non-spe-
cific binding was tested using a murine IgG antibody (Bio-
Rad Labs). For all identification experiments, a serum sample




Demographics of patients and samples are summa-
rised in Table 1. Greater than 80% of patients with
breast cancer were diagnosed with Stage 2A and
Stage 2B invasive ductal carcinoma (IDC). Themedian
age of patients was 52.6 years.
Serum protein profiling
Representative SELDI-TOF MS spectra are presented
in Figure 1. Following serum protein profiling and
spectrum pre-processing by the ProteinChip Software
v3.1, spectra of two breast cancer patients from batch
three were discarded due to aberrant normalisation
factors. The BMW detected a total of 76 peak clusters
across the spectra of all three batches.
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Table 1 Demographics of the study population.
Parameter Patients
n 140









IDC and ILC 4
Other 9
Sample storage time (months), 61.3 w49.1–76.4x
median wIQRx
Sample collection interval January 1993–December
2002
aPathologically determined stage and diagnosis. IQR, inter-
quartile range; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; other, mucinous, tubular, mixed,
unknown.
Figure 1 Example of protein profiles from sera of two patients with breast cancer stored for 10 (BC 1) and 120 (BC 2) months.
Table 2 Peak cluster information of the 14 peaks found significantly associated with sample storage duration.
Protein Peak, ANOVA, Regulationb, (Alleged) identityc
m/z p-valuea pattern
Albumin 2773 0.033 A m/z 2756 albumin25–48bqO
2789 0.001 A m/z 2756 albumin25–48bq(O)2
3089 0.016 A m/z 3089 albumin25–51b
3104 0.005 A m/z 3089 albumin25–51bqO
Fibrinogen 4215 -0.001 B Unknown fibrinogen fragment
5341 0.003 E m/z 5341 fibrinogen576–625b
5357 0.046 E m/z 5341 fibrinogen576–625bqO
5908 -0.001 B m/z 5908 fibrinogen576–630b
5929 -0.001 B m/z 5908 fibrinogen576–630bqO
6114 0.013 B m/z 5908 fibrinogen576–630b SPA adduct
11,091 0.003 B Unknown fibrinogen fragment
C3adesArg 4471 0.018 D m/z 8939 C3adesArg 672–747b double charge
8937 0.002 D m/z 8939 C3adesArg 672–747b
Unknown 4441 0.028 C Unknown
aBonferroni corrected p-values from ANOVA test of mean intensity differences between the discrete time intervals; b5 patterns
by which peak intensity was associated to sample storage duration: A, initial increase, followed by a gradual decrease; B,
continuous decrease; or C, continuous increase; D, initial increase, after which intensities remain stable; and E, stable up to
;8 years of storage time, followed by a decrease. cPeptides were structurally identified.
Influence of sample storage duration on the serum
protein profile
Mean log-Z peak intensity differences between the
four categories of sample storage times were inves-
tigated using ANOVA. In total, 14 of the 76 peak clus-
ters detected spectrum-wide were found to differ
significantly in mean log-Z intensity between the four
categories of sample storage time (Table 2). None of
the 14 peak clusters were related to patients’ age
(ANOVA; p)0.05) or stage of disease (t-test; p)0.05).
Five different patterns by which peak intensities
were associated with sample storage duration were
observed. These patterns (A–E) are depicted for five
representative peak clusters and shown in Figure 2.
For the peak clusters m/z 2773, 2789, 3089, and 3104,
a positive association with storage time was observed
up to duration of storage of ;5 years. After ;5 years
of storage, peak intensities gradually decreased with
time (Pattern A). Peak intensities of m/z 4215, 5908,
5929, 6114, and 11,091 were observed to continuously
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Figure 2 Representative examples of the five patterns (A–E) where peak intensities were associated with sample storage
duration (y-axis: Z-log transformed peak intensity, x-axis: sample storage duration in months).
decrease during sample storage time (Pattern B),
while the intensity of m/z 4441 was found to increase
over time (Pattern C). The fourth pattern (Pattern D),
observed in peak clusters m/z 4471, and m/z 8939,
showed an initial increase in peak intensity, after
which the intensities remained stable during pro-
longed storage. Finally, for clusters m/z 5341 and
m/z 5357, peak intensities were stable up to ;8 years
of storage, after which peak intensities decreased rap-
idly (Pattern E).
Peptide purification and (tentative) identification
The m/z 2756 and m/z 3089 peptides were present in
the pH 4 eluate after QhyperD fractionation of whole
serum. Following concentration of this fraction with
YM50 spin concentrators, the two peptides were
detected in the 50% ACN eluate. Since the peptides
were lost during the subsequent purification process-
es, their amino acid (aa) sequence was determined by
direct tandem MS on a PCI-interfaced Q-TOF. These
two peptides were identified as N-terminal fragments
of albumin (Figure 3). The theoretical mass of the
m/z 2756 peptide (24 aa) and the m/z 3089 peptide (27
aa) is 2754.10 Da and 3085.51 Da, respectively. The pI
of both fragments was 6.04.
Figure 4 depicts the correlation matrix presenting
the absolute Pearson’s correlation coefficients calcu-
lated for the peak intensities of the 14 peaks found to
be significantly associated with storage time. The
three peak clusters m/z 2756, 2773, and 2789 were
found highly correlated (Figure 4). Since the mass
deviation between m/z 2773, 2789 and 2756 is ;16
and 32 Da, these peptides most likely represent oxi-
dised forms of the m/z 2756 albumin fragment. Sim-
ilarly, m/z 3104 was found to be highly correlated to
m/z 3089 (Figure 4). Regarding the mass difference of
;16 Da, m/z 3104 is likely to represent the oxidised
form of the m/z 3089 albumin fragment. The pre-
sumed identities are supported by the observation
that all five peak clusters show a similar correlation
with sample storage time; an initial increase, followed
by a gradual decrease in peak intensity (Pattern A).
Following QhyperD fractionation, the m/z 5908 pep-
tide was detected in the flow-through. After concen-
tration of this fraction with YM50 spin concentrators,
the peptide was found in the flow-through. De-salting
with RP18 beads resulted in elution of the peptide in
the 50% ACN/0.1% TFA eluate. This fraction was again
concentrated with YM3 spin concentrators. Profiling
of the retentate revealed only peptides -5908 Da. In
prior identification attempts, the m/z 5908 peptide
was shown to degrade with increasing manipulation.
The detected peptides are therefore likely originating
from breakdown of the m/z 5908 peptide. Direct
sequencing of three peptides by tandem MS on a Q-
TOF confirmed the peptides to originate from a fibrin-
ogen alpha-E fragment (FGA576–630), 54 aa in length,
with a theoretical mass of 5904.22 Da and pI of 8.07
(Figure 5).
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Figure 3 Structural identification of the m/z 2756 and m/z 3089 peak clusters.
Direct sequencing of the m/z 2756 and m/z 3089 peak clusters. MS spectrum of the YM50 50% ACN eluate. All peptides were
sequenced with tandem MS using Q-TOF. Results from the MASCOT search for protein identification include start and end
positions of the peptide sequence starting from the amino acid terminal of the whole protein, the observed m/z wMr (obs)x,
transformed to its experimental mass wMr (expt)x, the calculated mass wMr (calc)x from the matched peptide sequence, their
mass difference (Delta), and the peptide sequence (in grey: the amino acid sequence determined by Q-TOF MS).
The m/z 4215, 5341, 5357, 5908, 5929, 6114 and
11,091 peak clusters were found to be highly corre-
lated with each other (Figure 4). Also, as the mass of
the m/z 5341 corresponds to the theoretical mass of
the 49 aa fibrinogen alpha-E fragment FGA576–625, the
correlated peptides most likely represent oxidised
fibrinogen fragments. The m/z 6114 cluster represents
the SPA adduct of m/z 5908 FGA576–630. Except for
m/z 5341 and m/z 5357, the (hypothesised) fibrinogen
fragments all show similar correlation with sample
storage time; gradual decrease in peak intensity over
sample storage time (Pattern B).
Following QhyperD fractionation, the m/z 8939 pep-
tide was detected in the flow-through. This fraction
was concentrated using YM50 spin concentrators. The
peptide was found in the 30% ACN eluate. De-salting
of the eluate with RP18 beads resulted in elution of
the peptide in the 50% ACN/0.1% TFA eluate. This was
then subjected to SDS-PAGE analysis. After staining,
a band in the 8.9 kDa region was visible. This band
was excised and subjected to passive elution followed
by tryptic digestion of the eluate. Profiling of the gel-
eluate confirmed the presence of the peptide. Peptide
mapping of the tryptic digest identified it as comple-
ment component 3 precursor with an estimated Z-
score of 1.57, 4% sequence coverage. Amino acid
sequencing of six peptides in the tryptic digest by
tandem MS on a Q-TOF identified the marker as C3a
des-arginine anaphylatoxin (C3adesArg, 61% sequence
coverage), a 76 amino acid protein with theoretical
mass 8939.46 Da and pI 9.54 (Figure 6). This identity
was confirmed by immunoassay using a C3a polyclo-
nal antibody (Abcam Ltd., Cambridge, UK). Profiling
of the eluates revealed the presence of a peak at m/z
8940. Non-specific binding, determined by binding to
murine IgG antibody, was very low.
The peak intensities of m/z 4471 and m/z 8939 were
highly correlated (Figure 4). From its mass, the m/z
4471 peak most likely represents the doubly charged
form of the m/z 8939 peak. The two peak clusters
show a similar correlation to sample storage duration;
an initial increase, after which peak intensities remain
stable over time (Pattern D). This finding helps con-
firm our hypothesis on the identity of m/z 4471.
Discussion
We studied archival sera from 140 patients with
breast cancer, stored at –308C from 1 to 11 years,
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Figure 4 Peak intensity correlation matrix for the 14 peaks found to be associated with sample storage duration (for clarity,
Pearson’s correlation coefficients were converted into absolute values).
using SELDI-TOF MS. Of the 76 peak clusters detected
throughout the spectrum, peak intensities of 14 peak
clusters were found to be significantly associated with
duration of sample storage. These were characterised
by five different patterns (A–E). These peak clusters
were structurally identified as C3adesArg and multiple
fragments of albumin and fibrinogen. These proteins
each appear to be associated with a distinct time-
dependent pattern, suggesting that every protein
might have a unique time-dependent profile. Combin-
ing multiple samples by splitting the dataset into four
categories of storage duration does not allow for
investigation of time-dependent patterns within each
individual sample. Thus, the observed patterns might
actually be comprised of multiple patterns, but we
only see the average. Our assumption that there is
only one distribution of samples with respect to pep-
tide levels and time dependence does, however, not
affect our primary observation that the (SELDI-TOF
MS) serum proteome is influenced by duration of
sample storage.
The susceptibility of detected proteins to sample
handling issues has been discussed in previous stud-
ies (8, 22, 31). A number of these proteins have, how-
ever, also been reported as potential cancer markers
(10, 11, 21). Although not tumour-derived, it is cur-
rently hypothesised that these presumed cancer-spe-
cific serum proteins are generated from a pool of
high-abundant founder proteins by tumour specific
proteases (11, 32, 33). Thus, these cleavage products
were found to be specific for both disease and pre-
analytical sample handling parameters. Assessment
of potential confounding pre-analytical parameters,
such as storage time, is critical in order to prevent
experimental variation to be interpreted erroneously
as disease associated variation. Also, regarding the
different non-linear patterns by which peak intensities
were found associated to storage duration, simply
applying linear corrections for sample storage dura-
tion may not suffice.
The albumin clusters
Four of the 14 significant peak clusters were observed
to initially increase in peak intensity up to ;5 years
of storage time, after which peak intensities
decreased (Pattern A). Two clusters (m/z 3089 and
m/z 3104) were structurally identified as albumin frag-
ments. The other two clusters (m/z 2773 and m/z 2789)
most likely correspond to oxidised forms of the struc-
turally identified m/z 2756 albumin fragment. We
hypothesise that the observed pattern is the result of
continuous in vitro proteolytic degradation of albumin
and its fragments.
Albumin is the most abundant serum protein
(30–50 mg/mL), comprising about one-half of serum
proteins (34). Detection of its proteolytic fragments as
markers for sample storage duration is therefore not
unexpected. The susceptibility of albumin to proteo-
lytic degradation during prolonged storage at –308C
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Figure 5 Structural identification of the m/z 5341 and m/z 5908 peak clusters.
Direct sequencing of the m/z 5341 and m/z 5908 peak clusters. MS spectrum of the YM3 retentate. Insert: SELDI-TOF MS
spectrum of the 50% ACN/0.1% TFA RP18 eluate (upper spectrum) and YM3 retentate (lower spectrum). All peptides were
sequenced with tandem MS using Q-TOF for confirmation. Results from the MASCOT search for protein identification include
start and end positions of the peptide sequence starting from the amino acid terminal of the whole protein, the observed
m/z wMr (obs)x, transformed to its experimental mass wMr (expt)x, the calculated mass wMr (calc)x from the matched peptide
sequence, their mass difference (Delta), and the peptide sequence (in grey: the amino acid sequence determined by Q-TOF
MS).
has been described previously by our group (22). We
observed the N-terminal albumin25–57 fragment to be
positively correlated with duration of storage
(1.4 years) at –308C. Similarly, peaks corresponding
to our m/z 2773 and m/z 3104 peak clusters were also
found to increase in peak intensity with increasing
storage time.
The fibrinogen clusters
Seven of the 14 peak clusters found significantly asso-
ciated with sample storage duration were identified
as (probable) fibrinogen fragments. The m/z 5908
FGA576–630, its oxidised form at m/z 5929, its SPA
adduct at m/z 6114, and the two alleged fibrinogen
fragments at m/z 4215 and m/z 11,091 all continuously
decreased in peak intensity with increasing sample
storage time (Pattern B). The m/z 5341 FGA576–625 and
its oxidised form at m/z 5357, however, decreased in
peak intensity only after ;6 years of storage (Pattern
E). These time-dependent changes in peak intensities
represent the characteristics of a sequential process
whereby fibrinogen fragments are proteolytically
degraded into subsequent smaller fragments.
Fibrinogen acts as the primary factor in the forma-
tion of blood clots by polymerisation to a fibrin net-
work and by enabling platelets to aggregate (35).
Similar to albumin, it is one of the most abundant
blood proteins (2–4 mg/mL). Thus, detection of pro-
teolytic fibrinogen fragments by SELDI-TOF MS as
indicators of sample storage duration is not surpris-
ing. In addition, various fibrinogen fragments have
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Figure 6 Structural identification of the m/z 8939 peak cluster.
Peptide mapping of the m/z 8939 peak cluster. MS spectrum of the m/z 8939 tryptic digest in the gel eluate. All peptides were
sequenced with tandem MS using Q-TOF for confirmation. Results from the MASCOT search for protein identification include
start and end positions of the peptide sequence starting from the amino acid terminal of the whole protein, the observed
m/z wMr (obs)x, transformed to its experimental mass wMr (expt)x, the calculated mass wMr (calc)x from the matched peptide
sequence, their mass difference (Delta), the number of missed cleavage sites for trypsin (Miss), and the peptide sequence (in
grey: the amino acid sequence determined by Q-TOF MS).
been found to be correlated with coagulation time.
While the m/z 5908 FGA576–630 continuously decreased
in peak intensity with coagulation time, the intensities
of all other peaks initially increased with coagulation
time, and then either remained stable (m/z 4215, m/z
11,091), or decreased (m/z 5341, m/z 6114) (8, 31, 36).
The different fibrinogen fragments have been
described in relation to various types of cancer. Vil-
lanueva et al. (11) reported a decreased serum m/z
5902 FGA576–630 peak intensity in thyroid cancer com-
pared to healthy individuals. In contrast, a 5.9 kDa
peak, not structurally identified, has been found
increased in patients with colorectal (37, 38), pancre-
atic (39), gastric (40), and lung cancer (41, 42), and in
hypopharyngeal squamous cell carcinoma (43). The
latter two studies also reported increased serum m/z
5339, 5927 and 6114 peak intensities in cancer cases
compared with controls (42, 43). Although the sera of
the groups compared in the above-mentioned studies
allegedly were collected during the same time inter-
val, accurate information on storage duration gener-
ally is not provided. Proteolytic degradation is,
however, known to decrease with decreasing temper-
ature. Since all sera investigated in these other stud-
ies were stored at –808C, influence of storage duration
on peak expression may be limited compared to our
study performed on samples at –308C. Regarding the
allegedly improved protein stability at –808C, future
biomarker studies should investigate samples stored
at –808C. In addition, sample banks should attempt to
maintain samples at –808C.
The C3adesArg clusters
We observed two peak clusters at m/z 8939 and m/z
4471, identified as C3adesArg and its doubly charged
form, to initially increase in peak intensity. After this
initial increase intensities remained constant during
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the remaining time interval (Pattern D). The acute
phase reactant C3 is the most abundant complement
protein in serum, normally at a concentration of
1.2 mg/mL (44). This protein supports the activation
of all three pathways of complement activation; the
classic, alternative, and lectin pathway (45, 46). Pro-
duced primarily in the liver and adipocytes, it is
formed by cleavage of C3 (185 kDa) by C3-conver-
tases into C3b (176 kDa) and C3a (9 kDa) (47). The
anaphylatoxin C3a is short lived in serum, as car-
boxypeptidases cleave the C-terminal arginine resi-
due to create the more stable but biologically inactive
C3adesArg (8.9 kDa) (46–48). Presumably, the conver-
sion of C3a to C3adesArg becomes complete during the
first months of storage, explaining the initial increase
in m/z 8939 peak intensity. As m/z 8939 C3adesArg peak
intensities remain stable following this increase, the
protein appears not to be susceptible to proteolytic
degradation; a finding that is corroborated by the
reported stability of C3a(desArg) to extremes of heat and
pH (49).
Complement can also be activated in vitro. Activa-
tion of the coagulation system is followed by activa-
tion of platelets, eliciting complement activation (50).
Although not structurally identified, Banks et al. (8)
reported that the intensity of an IMAC-Cu m/z 8939
and m/z 4477 peak significantly increased with pro-
longed coagulation times.
The 8.9 kDa C3adesArg peak has been proposed as a
biomarker in a number of studies investigating differ-
ent cancer types using serum SELDI-TOF MS analysis
(21, 51–54). This protein peak has been found
increased in different cancers including breast (18, 21,
24, 55), colorectal (51, 54), hepatocellular (52, 56, 57),
and chronic lymphoid malignancies (53). In contrast,
the studies of Hu et al. (58) and Han et al. (42) reported
an 8.9 kDa peak, not structurally identified, that was
decreased in sera from patients with breast and lung
cancer. Since information regarding sample collection
interval is rarely provided in reported studies, the
extent to which sample storage duration might have
biased reported results cannot be assessed.
Of particular interest are two studies published by
Li et al. (18, 21). Their first study reported an 8.9 kDa
peak that was increased in patients with breast cancer
compared to healthy controls. This peak had a very
high diagnostic utility (18). The sera from cancer
patients were, however, collected over a longer time
interval compared with control sera; the association
between sample storage duration and peak expres-
sion was not investigated. The increase in the 8.9 kDa
peak, identified as C3adesArg, in breast cancer patients
was confirmed by analysis of a second independent
sample set. All sera were collected within the same
2-year time period. When compared with their initial
study, the diagnostic performance of the 8.9 kDa peak
was much lower. This indicates probable bias due to
duration of sample storage in their initial study (21).
However, results of their initial study were indeed
reproducible, as shown in their validation study. The
sample set from their first study was stored at –808C,
a temperature at which the formation of C3adesArg
might be limited when compared with storage at
–308C. The sample set for their validation study was
stored at –308C. However, since all their validation
sera were obtained during the same time interval, the
samples of this set are unlikely to be biased by dura-
tion of sample storage. Although results may be
reproducible when samples of different groups differ
in storage time, investigators still need to assess
potential bias due to storage parameters. In addition,
in order to prevent samples from different patient
groups (i.e., cancer vs. control) being stored for dif-
ferent periods of time, biorepositories should collect
matched case and control samples.
We have not yet structurally identified the last peak
cluster at m/z 4441. This peak was found to be posi-
tively associated with sample storage duration. Most
likely, this m/z 4441 cluster represents a high-abun-
dant serum protein fragment, formed by continuous
non-specific proteolytic activity during storage at
–308C.
In conclusion, we identified SELDI-TOF MS peak
intensities of C3adesArg and various albumin and fibrin-
ogen fragments that were significantly associated
with storage duration of sera from 140 patients with
breast cancer. These proteins, however, have also
been described as potential cancer markers, render-
ing them specific to both disease and sample
handling issues. Thus, assessment of potential con-
founding pre-analytical parameters, such as sample
storage time, should be an integral component of bio-
marker discovery and validation studies. This is nec-
essary in order to prevent experimental variation to
be interpreted erroneously as variation that is asso-
ciated with disease. In addition, regarding the differ-
ent (non-)linear patterns by which peak intensities
were found to be associated with duration of sample
storage, applying simple linear corrections to account
for the duration of sample storage will not necessarily
suffice.
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